1. Search Result
Search Result
Results for "

ATP-dependent

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

3

Fluorescent Dye

2

Biochemical Assay Reagents

1

Peptides

2

Natural
Products

21

Recombinant Proteins

1

Isotope-Labeled Compounds

13

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148407

    Fluorescent Dye Others
    lucPpy-IN-1 (compound 9) is an ATP-dependent luciferase from Photinus pyralis (lucPpy) inhibitor with an IC50 value of 4.0 μM. lucPpy-IN-1 can be used for the research of target’s agentgability .
    lucPpy-IN-1
  • HY-E70034

    Endogenous Metabolite Metabolic Disease
    Galactokinase (BiGalK) is a phosphotransferase. Galactokinase catalyzes ATP-dependent phosphorylation of α-d-galactose to galactose 1-phosphate .
    Galactokinase (BiGalK)
  • HY-160007

    DNA/RNA Synthesis Cancer
    DHX9-IN-3 (Compound 621) is an ATP-dependent inhibitor of RNA helicase A (DHX9) with potential for cancer research .
    DHX9-IN-3
  • HY-160008

    DNA/RNA Synthesis Cancer
    DHX9-IN-4 (Compound 609) is an ATP-dependent inhibitor of RNA helicase A (DHX9) with potential for cancer research .
    DHX9-IN-4
  • HY-160010

    DNA/RNA Synthesis Cancer
    DHX9-IN-6 (Compound 620) is an ATP-dependent inhibitor of RNA helicase A (DHX9) with potential for cancer research .
    DHX9-IN-6
  • HY-145126

    CFTR Others
    CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    CP-628006
  • HY-156782

    DNA/RNA Synthesis Cancer
    DHX9-IN-1 (example 160) is an inhibitor of ATP-dependent RNA helicase A (DHX9), with the IC50 of 9.45 nM that has antitumor activity .
    DHX9-IN-1
  • HY-156784

    DNA/RNA Synthesis Cancer
    DHX9-IN-2 (example 31) is an inhibitor of ATP-dependent RNA helicase A (DHX9), with the IC50 of 0.0698 nM that has antitumor activity .
    DHX9-IN-2
  • HY-13328
    Sapanisertib
    Maximum Cited Publications
    30 Publications Verification

    INK-128; MLN0128; TAK-228

    mTOR Autophagy Cancer
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib
  • HY-137899

    Endogenous Metabolite Others
    Dephospho-CoA is A direct precursor of Coenzyme A (CoA). Dephospho-CoA kinase (DPCK) catalyzes the ATP-dependent phosphorylation of Dephospho-CoA, the final step in coenzyme A (CoA) biosynthesis .
    Dephospho-CoA
  • HY-109591B

    Biochemical Assay Reagents Others
    Oleoyl coenzyme A triammonium is the salt form of Oleoyl coenzyme A, which exhibits an inhibitory effects for neutral lipase. Oleoyl coenzyme A triammonium mediates ATP-dependent signal transduction pathway in plants .
    Oleoyl Coenzyme A triammonium
  • HY-128038

    Opioid Receptor Neurological Disease
    N-Desmethyl-loperamide is a major metabolite of loperamide, a drug that selectively activates peripheral μopioid receptors with a Ki value of 0.16 nM. N-Desmethyl-loperamide is a substrate of the ATP-dependent efflux transporter P-glycoprotein .
    N-Desmethyl-loperamide
  • HY-160685

    VEGFR Others
    GW809897X is a dual inhibitor of Fluc and VEGFR with IC50 of 0.58 μM and 65 nM, respectively. GW809897X is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential impact on Fluc reporter assays .
    GW809897X
  • HY-160684

    VEGFR Others
    GW701427A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.12 μM and 603 nM, respectively. GW701427A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays .
    GW701427A
  • HY-E70036

    Endogenous Metabolite Metabolic Disease
    Galcuronokinase (AtGalAK) is a member of the GHMP kinase family. Galcuronokinase (AtGalAK) catalyzes the ATP-dependent conversion of alpha-d-galacturonic acid (d-GalA) to alpha-d-galacturonic acid-1-phosphate (GalA-1-P) .
    Galcuronokinase (AtGalAK)
  • HY-160686

    Others Others
    GSK248233A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 1.03 μM and 2 nM, respectively. GSK248233A also shows activity against the AGC family. GSK248233A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays .
    GSK248233A
  • HY-160689

    UNC10112731

    c-Myc c-Kit Discoidin Domain Receptor PDGFR Others
    GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and PDGFRα by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene .
    GW694590A
  • HY-160687

    Others Others
    GW549390X is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.26 μM and 1.2 μM, respectively. GW549390X can bind to the ATP pocket of FLuc through the aniline side chain and is an ATP-competitive inhibitor of Fluc. GW549390X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases, with potential implications for Fluc reporter assays .
    GW549390X
  • HY-160691

    Others Others
    GW814408X is a kinase chemical genome group (KCGS) compound that inhibits the AURKC kinase involved in cell cycle progression, checkpoint regulation, and cell division. GW814408X exhibits cell line-dependent toxicity, e.g., cytotoxic effects on HeLa cells. GW814408X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays .
    GW814408X
  • HY-E70091

    DNA/RNA Synthesis Others
    T4 RNA ligase is an ATP-dependent RNA ligase that can catalyze the formation of phosphodiester bonds between the 5'-P end and the 3'-OH end of single-stranded RNA, single-stranded DNA or single nucleotides between molecules or within molecules. T4 RNA ligase is used for enzymatic low ribonucleotide synthesis and 3′ end labeling of RNA. It is mainly used for RNA and RNA, but can also be used for RNA and single nucleotides .
    T4 RNA ligase
  • HY-D1297

    Fluorescent Dye Others
    ER-Tracker dye is a derivative of BODIPY series dyes coupled with Glibenclamide (HY-15206), highly selective binding to the endoplasmic reticulum, non-toxic to cells at low concentrations, this type of dye is an environmentally sensitive probe, and formaldehyde treatment can still retain part of the fluorescence, with high fluorescence life, good extinction coefficient and other characteristics. Glibenclamide is an atp-dependent K + channel blocker (Kir6, KATP) and CFTR Cl-channel blocker that binds in the endoplasmic reticulum. ER-Tracker is not suitable for staining cells after fixation .
    ER-Tracker Green
  • HY-D1429

    Fluorescent Dye Others
    ER-Tracker dye is a derivative of BODIPY series dyes coupled with Glibenclamide (HY-15206), highly selective binding to the endoplasmic reticulum, non-toxic to cells at low concentrations, this type of dye is an environmentally sensitive probe, and formaldehyde treatment can still retain part of the fluorescence, with high fluorescence life, good extinction coefficient and other characteristics. Glibenclamide is an atp-dependent K + channel blocker (Kir6, KATP) and CFTR Cl-channel blocker that binds in the endoplasmic reticulum. ER-Tracker is not suitable for staining cells after fixation .
    ER-Tracker Blue-White DPX
  • HY-D1431

    Fluorescent Dye Cancer
    ER-Tracker dye is a derivative of BODIPY series dyes coupled with Glibenclamide (HY-15206), highly selective binding to the endoplasmic reticulum, non-toxic to cells at low concentrations, this type of dye is an environmentally sensitive probe, and formaldehyde treatment can still retain part of the fluorescence, with high fluorescence life, good extinction coefficient and other characteristics. Glibenclamide is an atp-dependent K + channel blocker (Kir6, KATP) and CFTR Cl-channel blocker that binds in the endoplasmic reticulum. ER-Tracker is not suitable for staining cells after fixation. Ex/Em=587/615 nm .
    ER-Tracker Red
  • HY-163105

    Microtubule/Tubulin Cancer
    Tubulin/NEDDylation-IN-1 (compound C11) is a dual inhibitor of tubulin (Microtubule/Tubulin)-NEDDylation (IC50 for tubulin=2.40 μM), which has strong anti-proliferative activity. Neddylation is a protein post-translational modification that covalently tags the ubiquitin-like protein NEDD8 to target proteins. Tubulin/NEDDylation-IN-1 forms hydrogen bonds with residues of tubulin and E1 NEDD8 activating enzyme (NAE) through methoxy and dithiocarbamate groups and inhibits NEDDylation and microtubulin in an ATP-dependent manner. tube polymerization .
    Tubulin/NEDDylation-IN-1
  • HY-153973

    DNA/RNA Synthesis Cancer
    WRN inhibitor 2 (example 118) is a WRN (Werner Syndrome ATP dependent helicase enzyme) inhibitor, with pIC50 ≥ 7.0 .
    WRN inhibitor 2
  • HY-156579

    DNA/RNA Synthesis Cancer
    WRN inhibitor 3 (example 110), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 3 can be used for the research of cancer .
    WRN inhibitor 3
  • HY-156580

    DNA/RNA Synthesis Cancer
    WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer .
    WRN inhibitor 4
  • HY-156581

    DNA/RNA Synthesis Cancer
    WRN inhibitor 5 (example 157), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 5 can be used for the research of cancer .
    WRN inhibitor 5
  • HY-153692

    DNA/RNA Synthesis Cancer
    WRN inhibitor 1 (example 7) is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor that inhibits WRN helicase domain activity. WRN inhibitor 1 has the potential to study cancer .
    WRN inhibitor 1
  • HY-10195B
    Ruboxistaurin hydrochloride
    5+ Cited Publications

    LY333531 hydrochloride

    PKC Metabolic Disease
    Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM .
    Ruboxistaurin hydrochloride
  • HY-10195
    Ruboxistaurin
    5+ Cited Publications

    LY333531

    PKC Metabolic Disease
    Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM .
    Ruboxistaurin
  • HY-N2306
    Aclacinomycin A
    3 Publications Verification

    Aclarubicin

    Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis .
    Aclacinomycin A
  • HY-N2306A

    Aclarubicin hydrochloride

    Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic Cancer
    Aclacinomycin A (Aclarubicin) hydrochloride is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A hydrochloride is an inhibitor of topoisomerase I and II. Aclacinomycin A hydrochloride inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A hydrochloride might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis .
    Aclacinomycin A hydrochloride
  • HY-10195BS

    Isotope-Labeled Compounds PKC Metabolic Disease
    Ruboxistaurin-d6 (hydrochloride) is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2].
    Ruboxistaurin-d6 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: